Literature DB >> 30630955

Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies.

Xue-Ning Shen1, Li-Dong Niu1, Yan-Jiang Wang2, Xi-Peng Cao3, Qiang Liu4, Lan Tan1, Can Zhang5, Jin-Tai Yu6.   

Abstract

OBJECTIVE: Inflammation plays a crucial role in the pathogenesis of mild cognitive impairment (MCI) and Alzheimer's disease (AD). Our study aimed to analyse previous inconsistent results of inflammatory markers in AD and MCI quantitatively.
METHODS: Studies reporting concentrations of peripheral or cerebrospinal fluid (CSF) markers were included, and eligible data on AD, MCI and control were extracted. Pooled Hedges's g was adopted to illustrate comparisons, and various confounding factors were used to explore sources of heterogeneity.
RESULTS: A total of 170 studies were included in the meta-analysis and systematic review, which demonstrated increased peripheral levels of high-sensitivity C reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour necrosis factor receptor 1 (sTNFR1) (0.763, p<0.05), soluble tumour necrosis factor receptor 2 (sTNFR2) (0.354, p<0.005), alpha1-antichymotrypsin (α1-ACT) (1.217, p<0.005), IL-1β (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0.434, p<0.05), monocyte chemoattractant protein-1 (MCP-1) (0.798, p<0.005), transforming growth factor-beta 1 (1.009, p<0.05), soluble triggering receptor expressed on myeloid cells2 (sTREM2) (0.587, p<0.001), YKL-40 (0.849, p<0.001), α1-ACT (0.638, p<0.001), nerve growth factor (5.475, p<0.005) and visinin-like protein-1 (VILIP-1) (0.677, p<0.005), in AD compared with the control. Higher levels of sTNFR2 (0.265, p<0.05), IL-6 (0.129, p<0.05) and MCP-1 (0.779, p<0.05) and lower levels of IL-8 (-1.293, p<0.05) in the periphery, as well as elevated concentrations of YKL-40 (0.373, p<0.05), VILIP-1 (0.534, p<0.005) and sTREM2 (0.695, p<0.05) in CSF, were shown in MCI compared with the control. Additionally, increased peripheral sTNFR1 (0.582, p<0.05) and sTNFR2 (0.254, p<0.05) levels were observed in AD compared with MCI.
CONCLUSION: Significantly altered levels of inflammatory markers were verified in comparison between AD, MCI and control, supporting the notion that AD and MCI are accompanied by inflammatory responses in both the periphery and CSF. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Alzheimer’s disease; cerebrospinal fluid; inflammation; meta; mild cognitive impairment; peripheral blood

Mesh:

Substances:

Year:  2019        PMID: 30630955     DOI: 10.1136/jnnp-2018-319148

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  69 in total

Review 1.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

2.  Plasma Biomarkers of Alzheimer's Disease in African Americans.

Authors:  Kaancan Deniz; Charlotte C G Ho; Kimberly G Malphrus; Joseph S Reddy; Thuy Nguyen; Troy P Carnwath; Julia E Crook; John A Lucas; Neill R Graff-Radford; Minerva M Carrasquillo; Nilüfer Ertekin-Taner
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

3.  Infliximab and Tocilizumab Reduce Anxiety-Like Behaviour and Improve Cognitive Performance in a Juvenile Collagen-Induced Arthritis Rat Model.

Authors:  Frideriki Poutoglidou; Chryssa Pourzitaki; Maria Eleni Manthou; Athanasios Saitis; Foteini Malliou; Dimitrios Kouvelas
Journal:  Inflammation       Date:  2021-09-13       Impact factor: 4.092

4.  Systemic inflammatory markers in relation to cognitive function and measures of brain atrophy: a Mendelian randomization study.

Authors:  Jiao Luo; Saskia le Cessie; Gerard Jan Blauw; Claudio Franceschi; Raymond Noordam; Diana van Heemst
Journal:  Geroscience       Date:  2022-06-11       Impact factor: 7.713

Review 5.  The impact of physical activity on blood inflammatory cytokines and neuroprotective factors in individuals with mild cognitive impairment: a systematic review and meta-analysis of randomized-controlled trials.

Authors:  Chuyi Ma; Miaoran Lin; Jiahui Gao; Shurui Xu; Li Huang; Jingfang Zhu; Jia Huang; Jing Tao; Lidian Chen
Journal:  Aging Clin Exp Res       Date:  2022-01-13       Impact factor: 3.636

Review 6.  Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders.

Authors:  Anna Morozova; Yana Zorkina; Olga Abramova; Olga Pavlova; Konstantin Pavlov; Kristina Soloveva; Maria Volkova; Polina Alekseeva; Alisa Andryshchenko; Georgiy Kostyuk; Olga Gurina; Vladimir Chekhonin
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

Review 7.  Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies.

Authors:  Henrik Zetterberg; Barbara B Bendlin
Journal:  Mol Psychiatry       Date:  2020-04-06       Impact factor: 15.992

8.  Obesity-induced cognitive impairment in older adults: a microvascular perspective.

Authors:  Priya Balasubramanian; Tamas Kiss; Stefano Tarantini; Ádám Nyúl-Tóth; Chetan Ahire; Andriy Yabluchanskiy; Tamas Csipo; Agnes Lipecz; Adam Tabak; Adam Institoris; Anna Csiszar; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-12-18       Impact factor: 4.733

9.  NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline.

Authors:  Constance Delaby; A Julian; G Page; S Ragot; Sylvain Lehmann; M Paccalin
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

10.  The Relationship Between Mild Cognitive Impairment and Anti-Inflammatory/Pro-Inflammatory Nutrients in the Elderly in Northern China: A Bayesian Kernel Machine Regression Approach.

Authors:  Ruiqiang Li; Wenqiang Zhan; Xin Huang; Limin Zhang; Zechen Zhang; Meiqi Zhou; Zhihong Wang; Yuxia Ma
Journal:  J Inflamm Res       Date:  2022-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.